@article{uoadl:3347438,
    volume = "4",
    number = "12",
    pages = "1847-1857",
    journal = "Nature Metabolism",
    keywords = "atorvastatin;  clofibrate;  coumarin;  cyclosporine;  fenofibrate;  glimepiride;  pravastatin;  rosuvastatin;  simvastatin;  tacrolimus;  warfarin;  fenofibrate;  peroxisome proliferator activated receptor alpha, adult;  Article;  artificial ventilation;  blood cell count;  body mass;  cardiovascular disease;  chronic kidney failure;  clinical trial;  controlled study;  coronavirus disease 2019;  coughing;  diabetes mellitus;  diastolic blood pressure;  disease severity;  disease severity assessment;  dyspnea;  estimated glomerular filtration rate;  ethnic or racial aspects;  fatigue;  female;  heart rate;  human;  hypertension;  in vitro study;  lipid metabolism;  major clinical study;  male;  modulation;  multicenter study;  myalgia;  oxygen saturation;  oxygen therapy;  people by smoking status;  randomized controlled trial;  Severe acute respiratory syndrome coronavirus 2;  sleep disordered breathing;  systolic blood pressure;  aged;  lipid metabolism;  middle aged, Adult;  Aged;  COVID-19;  Female;  Fenofibrate;  Humans;  Lipid Metabolism;  Male;  Middle Aged;  PPAR alpha;  SARS-CoV-2",
    BIBTEX_ENTRY = "article",
    year = "2022",
    author = "Chirinos, J.A. and Lopez-Jaramillo, P. and Giamarellos-Bourboulis, E.J. and Dávila-del-Carpio, G.H. and Bizri, A.R. and Andrade-Villanueva, J.F. and Salman, O. and Cure-Cure, C. and Rosado-Santander, N.R. and Cornejo Giraldo, M.P. and González-Hernández, L.A. and Moghnieh, R. and Angeliki, R. and Cruz Saldarriaga, M.E. and Pariona, M. and Medina, C. and Dimitroulis, I. and Vlachopoulos, C. and Gutierrez, C. and Rodriguez-Mori, J.E. and Gomez-Laiton, E. and Cotrina Pereyra, R. and Ravelo Hernández, J.L. and Arbañil, H. and Accini-Mendoza, J. and Pérez-Mayorga, M. and Milionis, C. and Poulakou, G. and Sánchez, G. and Valdivia-Vega, R. and Villavicencio-Carranza, M. and Ayala-García, R.J. and Castro-Callirgos, C.A. and Alfaro Carrasco, R.M. and Garrido Lecca Danos, W. and Sharkoski, T. and Greene, K. and Pourmussa, B. and Greczylo, C. and Ortega-Legaspi, J. and Jacoby, D. and Chittams, J. and Katsaounou, P. and Alexiou, Z. and Sympardi, S. and Sweitzer, N.K. and Putt, M. and Cohen, J.B. and Barrantes Alarcón, C. and Mendoza Sanchez, D.M. and Bernales Salas, E.F. and Chamby Díaz, C.J. and Vargas Gómez, U.M. and Salinas Herrera, C.D. and Barriga Triviños, N.L. and Coacalla Guerra, J.C. and Marrón Veria, E. and William, P. and Espinoza-Rojas, H. and Benites-Flores, I.R. and Segura-Saldaña, P.A. and the FERMIN Investigators",
    abstract = "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cytotoxicity may involve inhibition of peroxisome proliferator-activated receptor alpha. Fenofibrate activates peroxisome proliferator-activated receptor alpha and inhibits SARS-CoV-2 replication in vitro. Whether fenofibrate can be used to treat coronavirus disease 2019 (COVID-19) infection in humans remains unknown. Here, we randomly assigned inpatients and outpatients with COVID-19 within 14 d of symptom onset to 145 mg of oral fenofibrate nanocrystal formulation versus placebo for 10 d, in a double-blinded fashion. The primary endpoint was a severity score whereby participants were ranked across hierarchical tiers incorporating time to death, mechanical ventilation duration, oxygenation, hospitalization and symptom severity and duration. In total, 701 participants were randomized to fenofibrate (n = 351) or placebo (n = 350). The mean age of participants was 49 ± 16 years, 330 (47%) were female, mean body mass index was 28 ± 6 kg/m2 and 102 (15%) had diabetes. Death occurred in 41 participants. Compared with placebo, fenofibrate had no effect on the primary endpoint. The median (interquartile range) rank in the placebo arm was 347 (172, 453) versus 345 (175, 453) in the fenofibrate arm (P = 0.819). There was no difference in secondary and exploratory endpoints, including all-cause death, across arms. There were 61 (17%) adverse events in the placebo arm compared with 46 (13%) in the fenofibrate arm, with slightly higher incidence of gastrointestinal side effects in the fenofibrate group. Overall, among patients with COVID-19, fenofibrate has no significant effect on various clinically relevant outcomes (NCT04517396). © 2022, The Author(s), under exclusive licence to Springer Nature Limited.",
    title = "A randomized clinical trial of lipid metabolism modulation with fenofibrate for acute coronavirus disease 2019",
    doi = "10.1038/S42255-022-00698-3"
}